Ephrin-A1 is a negative regulator in glioma through down-reguation of EphA2 and FAK

International Journal of Oncology

Volumn 30, Issue 4, 2007, Pages 865-871

  Liu, Dong Ping ^a   Wang, Yan ^a   Koeffler, H Phillip ^b   Xie, Dong ^a  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

EphA2; Ephrin A1; FAK; Gliomas

Indexed keywords

EPHRIN A1; EPHRIN A2; FOCAL ADHESION KINASE;

ARTICLE; BRAIN TUMOR; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; CELL TRANSFORMATION; CHEMISTRY; DOWN REGULATION; GENETICS; GLIOMA; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY;

BRAIN NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; EPHRIN-A1; EPHRIN-A2; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GLIOMA; HUMANS; TUMOR CELLS, CULTURED;

EID: 34247860854     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.4.865     Document Type: Article

References (39)

1. Eph Nomenclature Committee: Unified nomenclature for Eph family receptors and their ligands, the ephrins. Cell 90: 403-404, 1997.
2. Palmer A and Klein R: Multiple roles of ephrins in morphogenesis, neuronal networking, and brain function. Genes Dev 17: 1429-1450, 2003. (Pubitemid 36734700)
3. Wilkinson DG: Eph receptors and ephrins: regulators of guidance and assembly. Int Rev Cytol 196: 177-244, 2000. (Pubitemid 30130841)
4. Wilkinson DG: Multiple roles of EPH receptors and ephrins in neural development. Nat Rev Neurosci 2: 155-164, 2001.
5. Brantley DM, Cheng N, Thompson E, et al: Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 21: 7011-7026, 2002.
6. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR and Kinch MS: EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61: 2301-2306, 2001.
7. Han L, Dong Z, Qiao Y, Kristensen GB, Holm R, Nesland JM and Suo Z: The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. Gynecol Oncol 99: 278-286, 2005. (Pubitemid 41502831)
8. Thaker PH, Deavers M, Celestino J, et al: EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 10: 5145-5150, 2004. (Pubitemid 39099789)
9. Nakamura R, Kataoka H, Sato N, et al: EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci 96: 42-47, 2005.
10. Duxbury MS, Ito H, Zinner MJ, Ashley SW and Whang EE: Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness. Biochem Biophys Res Commun 320: 1096-1102, 2004. (Pubitemid 38916656)
11. Duxbury MS, Ito H, Zinner MJ, Ashley SW and Whang EE: EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene 23: 1448-1456, 2004. (Pubitemid 38406840)
12. Zeng G, Hu Z, Kinch MS, et al: High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol 163: 2271-2276, 2003.
13. Walker-Daniels J, Coffman K, Azimi M, et al: Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 41: 275-280, 1999.
14. Easty DJ, Guthrie BA, Maung K, et al: Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression. Cancer Res 55: 2528-2532, 1995.
15. Seftor EA, Meltzer PS, Schatteman GC, et al: Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasculogenic mimicry. Crit Rev Oncol Hematol 44: 17-27, 2002.
16. Kinch MS and Carles-Kinch K: Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. Clin Exp Metastasis 20: 59-68, 2003. (Pubitemid 36308137)
17. Wykosky J, Gibo DM, Stanton C and Debinski W: EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res 3: 541-551, 2005. (Pubitemid 41567273)
18. Kikawa KD, Vidale DR, van Etten RL and Kinch MS: Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. J Biol Chem 277: 39274-39279, 2002.
19. Carles-Kinch K, Kilpatrick KE, Stewart JC and Kinch MS: Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 62: 2840-2847, 2002. (Pubitemid 34525769)
20. Zantek ND, Azimi M, Fedor-Chaiken M, Wang B, Brackenbury R and Kinch MS: E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ 10: 629-638, 1999. (Pubitemid 29455727)
21. Deen DF, Chiarodo A, Grimm EA, et al: Brain Tumor Working Group Report on the 9th International Conference on Brain Tumor Research and Therapy. Organ System Program National Cancer Institute. J Neurooncol 16: 243-272, 1993.
22. Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW and Burger PC: Histopathology, classification, and grading of gliomas. Glia 15: 211-221, 1995.
23. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics, 1999. CA Cancer J Clin 49: 8-31, 1999.
24. Nakamoto M and Bergemann AD: Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech 59: 58-67, 2002.
25. Noblitt LW, Bangari DS, Shukla S, Knapp DW, Mohammed S, Kinch MS and Mittal SK: Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther 11: 757-766, 2004. (Pubitemid 39488474)
26. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL and Pasquale EB: The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19: 6043-6052, 2000. (Pubitemid 32039378)
27. Tong X, Xie D, O'Kelly J, Miller CW, Muller-Tidow C and Koeffler HP: Cyr61, a member of CCN family, is a tumor suppressor in non-small cell lung cancer. J Biol Chem 276: 47709-47714, 2001. (Pubitemid 37373161)
28. Xie D, Miller CW, O'Kelly J, et al: Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. J Biol Chem 276: 14187-14194, 2001. (Pubitemid 37391805)
29. Trainer DL, Kline T, McCabe FL, et al: Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int J Cancer 41: 287-296, 1988.
30. Miao H, Burnett E, Kinch M, Simon E and Wang B: Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol 2: 62-69, 2000.
31. Carter N, Nakamoto T, Hirai H and Hunter T: EphrinA1-induced cytoskeletal re-organization requires FAK and p130(cas). Nat Cell Biol 4: 565-573, 2002.
32. Carragher NO, Fincham VJ, Riley D and Frame MC: Cleavage of focal adhesion kinase by different proteases during SRC-regulated transformation and apoptosis. Distinct roles for calpain and caspases. J Biol Chem 276: 4270-4275, 2001. (Pubitemid 37371515)
33. Carragher NO, Westhoff MA, Riley D, et al: v-Src-induced modulation of the calpain-calpastatin proteolytic system regulates transformation. Mol Cell Biol 22: 257-269, 2002. (Pubitemid 33144273)
34. Wang D, Grammer JR, Cobbs CS, et al: p125 focal adhesion kinase promotes malignant astrocytoma cell proliferation in vivo. J Cell Sci 113: 4221-4230, 2000. (Pubitemid 32000689)
35. Aguirre Ghiso JA: Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene 21: 2513-2524, 2002.
36. Chan PC, Liang CC, Yu KC, Chang MC, Ho WL, Chen BH, and Chen HC: Synergistic effect of focal adhesion kinase overexpression and hepatocyte growth factor stimulation on cell transformation. J Biol Chem 277: 50373-50379, 2002.
37. Leyton J, Garcia-Marin LJ, Tapia JA, Jensen RT and Moody TW: Bombesin and gastrin releasing peptide increase tyrosine phosphorylation of focal adhesion kinase and paxillin in nonsmall cell lung cancer cells. Cancer Lett 162: 87-95, 2001.
38. Hauck CR, Sieg DJ, Hsia DA, Loftus JC, Gaarde WA, Monia BP and Schlaepfer DD: Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells. Cancer Res 61: 7079-7090, 2001.
39. Noblitt LW, Bangari DS, Shukla S, Mohammed S and Mittal SK: Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy. Cancer Gene Ther 12: 46-53, 2005. (Pubitemid 39665242)